MiR-214 targets validated in cancer include TFAP2 and ITGA3 in melanoma, ING4 in pancreatic cancer, PTEN in stomach cancer, LZTS1 in osteosarcoma, PTEN and P53 in ovarian cancer, and ERK1/2 in cutaneous squamous cell carcinoma [51,248]. This evidence concerns the gene TP53 and cancer.